Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Apis Flagship Fund Daniel Barker | “The top contributor in Q4 was Celcuity, a healthcare name highlighted in our last quarterly letter, which added 3.8% during the quarter and 4.4% for the full year. BSD Analysis: Celcuity is a high-risk, high-upside oncology play built around the idea that signaling-pathway biology can be measured more precisely than legacy biomarkers. Its CELsigna platform aims to identify which tumors are actually dependent on specific pathways, a nuance that could materially improve drug response rates. The market treats this like another early-stage biotech science project, but the diagnostic-plus-therapy angle creates differentiated optionality. Clinical readouts will drive everything, and volatility is guaranteed. What makes Celcuity interesting is that success doesn't require curing cancer — just proving superior patient selection. If the platform works, partners and acquirers show up fast. This is binary, but the payoff is asymmetric.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.